Company Overview

Oligomerix has the potential to provide a transformational approach to treatment concerning Alzheimer’s Disease and Dementia Related Disorders. The Company’s novel and proprietary small molecule inhibitor and biomarker platform target the global unmet need of a successful therapeutic program for AD, which currently impacts more than 5.7 million Americans.

With more than 11 years of tau research experience and support from the National Institute on Aging at NIH, Oligomerix has developed a comprehensive package of novel CNS small molecule leads, biomarkers, and biotechnology that will help enable a de-risked, expedited clinical development program by a strategic partner.